Wang Ying, Wang Ying, Sui Yi, Yu Hongshuang, Shen Xiaoheng, Chen Shengdi, Pei Gang, Zhao Jian, Ding Jianqing
Institute of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
J Alzheimers Dis. 2015;45(4):1185-95. doi: 10.3233/JAD-143183.
Alzheimer's disease (AD) is a common neurodegenerative disease affecting cognitive function in the elderly, which is characterized by the presence of extracellular deposits of insoluble amyloid-β plaques and neuronal loss. Modern pharmacology and drug development usually follow a single-target principle, which might contribute to the failure of most compounds in clinical trials against AD. Considering AD is a multifactorial disease, a combination therapeutic strategy that applies drugs with different mechanisms would be an alternative way. Smart Soup (SS), a Traditional Chinese Medicine formula, is composed of three herbaceous plants and has been applied in the treatment of amnesia in China for hundreds of years. In this work, we studied the clinical potency of the combination of SS and Aricept in AD therapy. In the in vivo model, both longevity and locomotive activity of AD transgenic Drosophila were improved remarkably in the combined medicine treated group. We also observed less amyloid-β deposition and retarded neuronal loss following the combined drug treatment. In the retrospective cohort study, we found the combination therapy exerted better therapeutic effect on AD patients. Our study revealed that combination therapy with multiple drug targets did have a better therapeutic outcome. It provides a new strategy to develop an optimum pharmaceutical approach against AD.
阿尔茨海默病（AD）是一种影响老年人认知功能的常见神经退行性疾病，其特征是存在不溶性淀粉样β斑块的细胞外沉积物和神经元丢失。现代药理学和药物开发通常遵循单一靶点原则，这可能是大多数针对AD的化合物在临床试验中失败的原因。鉴于AD是一种多因素疾病，应用具有不同作用机制的药物的联合治疗策略可能是一种替代方法。聪耳汤（SS）是一种中药配方，由三种草本植物组成，在中国已被用于治疗失忆症数百年。在这项研究中，我们研究了SS与安理申联合治疗AD的临床疗效。在体内模型中，联合药物治疗组中AD转基因果蝇的寿命和运动活性均得到显著改善。联合药物治疗后，我们还观察到淀粉样β沉积减少，神经元丢失延缓。在回顾性队列研究中，我们发现联合治疗对AD患者具有更好的治疗效果。我们的研究表明，多靶点联合治疗确实具有更好的治疗效果。它为开发针对AD的最佳药物治疗方法提供了一种新策略。
